

**CLINICAL REVIEW**

# Sleep Apnea: From the Nose to the Heart

Michael J. Cutler, MS, Abdul-Latif Hamdan, MD, Mohamed H. Hamdan, MD, Karthik Ramaswamy, MD, and Michael L. Smith, PhD

**Background:** Obstructive sleep apnea (OSA) is a disorder consisting of repetitive obstruction of the upper airway during sleep accompanied by ineffective respiratory effort.

**Methods:** We developed this clinical review using an extensive MEDLINE review of the literature and data from our laboratories. This review examines (1) the prevalence of OSA; (2) the pathophysiology involved including the causes of obstruction, the physiologic stimuli, and resulting autonomic changes; (3) the cardiovascular manifestations; and (4) the therapeutic approaches to patients with OSA with emphasis on arrhythmia management.

**Results and Conclusions:** OSA is highly prevalent and largely underdiagnosed. As part of a much broader spectrum of respiratory disturbances during sleep, OSA can result in a multitude of systemic manifestations. Structural changes occur in the airway to obstruct airflow during OSA, and the resulting apnea activates hypoxic and hypercapnic reflexes, which in turn lead to profound elevation in sympathetic nerve activity and cyclical changes in parasympathetic nerve activity. These autonomic effects are thought to contribute to the associated cardiovascular diseases (eg, hypertension) and frequently observed brady- and tachyarrhythmias. The ultimate goal in the treatment of OSA is to restore airway patency and sleep continuity and to improve daytime functioning and quality of life. Treatment usually results in improvement of clinical symptoms. (J Am Board Fam Pract 2002;15:128–41.)

Sleep-disordered breathing is a term used broadly to describe regular respiratory disturbances during sleep, a condition for which primary care physicians have very limited formal training.<sup>1</sup> Included in this broad description is the sleep apnea-hypopnea syndrome, which can be further divided into three types: central, obstructive, and mixed. Central sleep apnea-hypopnea is a period of at least 10 seconds during which airflow is absent (apnea) combined with a complete or partial absence of respiratory effort.<sup>2</sup> Obstructive sleep apnea-hypopnea (OSA) consists of repetitive obstruction of the upper airway during sleep in which ineffective respiratory

efforts occur. Mixed sleep apnea-hypopnea is a period of either complete or diminished airflow resulting from a combination of central (lack of respiratory drive and, thus, breathing effort) and obstructive mechanisms. Pure central sleep apnea-hypopnea has been found to make up less than 10% of the patients at most sleep laboratories.<sup>2</sup> We will, therefore, focus this review on the more prevalent type of sleep-disordered breathing, OSA.

## Methods

We undertook an extensive MEDLINE review of the literature using the key words “sleep apnea,” “arrhythmias,” and “autonomic nervous system,” as well as data from our laboratories. This review examines (1) the prevalence of OSA; (2) the pathophysiologic mechanisms involved, including the causes of obstruction, the physiologic stimuli, and resulting autonomic changes; (3) the cardiovascular manifestations; and (4) the therapeutic approaches to patients who suffer from OSA, with emphasis on arrhythmia management.

## Prevalence

Even though OSA was defined more than 30 years ago, only in the past decade has awareness of the

Submitted, revised, 1 October, 2001.

From the Department of Integrative Physiology (MJC, MLS), University of North Texas Health Science Center at Fort Worth; the Department of Otolaryngology (ALH), American University of Beirut, Beirut, Lebanon; and the Southwestern Medical Center (MHH, KR), University of Texas, and Dallas Veteran's Affairs Medical Center (MHH, KR), Dallas. Address reprint requests to Michael L. Smith, PhD, Department of Integrative Physiology, UNT Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX 76107.

This review was supported in part by a grant from National Heart Lung and Blood Institute (HL49266 to MLS) and a research fellowship from the American Heart Association (to MJC).

syndrome among both medical professionals and the public become more common.<sup>3</sup> Despite this increased awareness, many patients have treatable OSA undiagnosed by both the primary care physician and the specialist.<sup>3-5</sup> The incidence of OSA among middle-aged men and women varies from 1% to 5% and 1.2% to 2.5%, respectively,<sup>6-10</sup> and has been shown to increase with age.<sup>11,12</sup> In one study done on 358 elderly volunteers (mean age of 72.4 years), the incidence of OSA was found to be 7%. Furthermore, there was a correlation between age and the apnea index.<sup>13</sup> The variability in the incidence of OSA is thought to be due to differences in population studied (age, body mass index, genetic factors), methods of monitoring sleep and respiration, criteria for defining an abnormal respiratory event, and the number of apneas or hypopneas per hour of sleep considered abnormal.<sup>3,4</sup>

The incidence of OSA is higher in African Americans than it is in white Americans,<sup>14</sup> and it is likely that the prevalence in general is much greater than that reflected by sleep clinic referrals, particularly among elderly persons and women.<sup>14-16</sup> In addition, it is believed that as much as 40% of patients with essential hypertension have undiagnosed and therefore untreated OSA.<sup>5,17-19</sup> Thus, although the estimates of incidence vary, it is clear that OSA is a syndrome that pervades the general population and is currently underdiagnosed.

## Pathophysiology

### *Causes of Obstruction*

Sounds of snoring originate in the collapsible part of the airway, where there is no rigid support, which implicates a primary role of the nasopharyngeal inlet, pharynx, and tongue in sleep and breathing disturbances. The key force that promotes the closure of the upper airway is the negative pressure applied to the airway during inspiration, which is determined by the inspiratory effort and the physical dimensions of the upper airway. Any narrowing from the level of the anterior nares, nasal cavity proper, and nasopharynx will lead to greater negative pressure required to produce any given level of airflow into the lungs.<sup>20</sup> The primary force holding the airway open is the activity of the dilator muscles that give tone and tension to the pharyngeal muscles. One suggested mechanism that might be important in producing upper airway obstruction is a difference in timing between the hypoxic-hyper-


capnic drive to inspiration and activation of the dilator muscles.<sup>21</sup> If inspiration is initiated before there is any activation of the dilator muscles, the upper airway is at risk of closure by this suction effect.<sup>22</sup>

Another cause of OSA is nasal obstruction. The nose, best viewed as a variable resistor, contributes to nearly 40% of total airway resistance.<sup>23</sup> This resistance is greatly influenced by the vasomotor reaction of the nose to several factors, such as hormonal effects, metabolic changes, and numerous pharmacologic agents.<sup>23</sup> Olsen et al<sup>24</sup> measured the respiratory effort in a patient during sleep and suggested that the oral airway resistance was greater than the nasal airway resistance. With the nasal pathway being the preferred route for nocturnal breathing, an increase in nasal resistance will invariably increase the possibility of collapse of the nonrigid portion of the upper airway, namely, the pharynx. Causes of nasal airway obstruction are many, including enlarged adenoids commonly seen in patients with allergic rhinitis and bony structural defects.

### *Physiologic Stimuli*

To understand OSA fully, it is vital to understand the physiologic stimuli that initiate the arousal and the increased inspiratory effort associated with the end of an apneic episode. In a patient with OSA the typical progression of each apnea and the cardiovascular consequences can be summarized as follows (Figure 1): First, there is an initial decrease in the drive to breathe caused by decreased sensitivity of the peripheral and central chemoreceptors. As a result, the airway collapses, leading to the apneic event that limits gas exchange at the lungs. The subsequent hypoxic-hypercapnic state increases the drive to breathe. The breathing effort, however, is impeded by the obstructed airway, which causes further impairment of gas exchange. Eventually, the severe hypoxia and hypercapnia produce a breathing effort adequate to terminate the apneic event. This effort often elicits arousal, which disrupts the progression of sleep, and results in disturbed sleep architecture. The cycle, as illustrated in Figure 1, repeats many times during the night.

The primary stimuli for the cardiovascular and respiratory responses that occur during apnea are the resulting hypoxemia and hypercapnia. As  $P_{aO_2}$  levels decrease and  $P_{aCO_2}$  levels increase during apnea, chemoreceptors in the carotid bodies, aortic



**Figure 1.** (Top panel) Schematic of obstructive sleep apnea (OSA) cycle, with accompanying sympathetic neural and cardiovascular responses. Bottom panel - sample tracings of cardiovascular and sympathetic neural activity responses to an episode of OSA. Of note are a progressive rise in arterial pressure and sympathetic neural activity during apnea and bradycardia toward the end of the apneic episode. HR = heart rate, BP = blood pressure, SVR = systemic vascular resistance, Resp = respiration, SaO<sub>2</sub> = arterial oxygen saturation, ECG = electrocardiogram, ABP = arterial blood pressure, SNA = sympathetic neural activity.

arch, and brainstem (medulla) are activated, leading to an increased inspiratory drive. Although hypoxemia plays a major role, the chemoreceptor sensitivity to carbon dioxide is the primary drive for increased ventilation. In addition, changes in intrathoracic pressure (associated with ineffective inspiratory efforts) during apnea have been shown

to play a role in the acute cardiovascular responses.<sup>25,26</sup> These changes in intrathoracic pressure can influence venous return, ventricular filling, arterial and cardiopulmonary baroreflexes, and the release of atrial natriuretic peptide.<sup>4,27</sup> Thus, it is the interplay of all these physiologic stimuli that result in the autonomic and cardiovascular changes associated with OSA.

### Acute Autonomic Manifestations

The changes in heart rate and blood pressure associated with acute OSA are thought to be primarily a result of alterations in the autonomic nervous system during each apneic episode.<sup>28,29</sup> During each apneic event there is a progressive increase in sympathetic nerve activity throughout the episode, reaching a peak at termination of the apnea, after which there is a marked decrease during recovery.<sup>21,30,31</sup>

The increase in sympathetic nerve activity during apnea is mainly the result of acute hypoxia and hypercapnia.<sup>30-33</sup> Leuenberger et al<sup>30</sup> showed that with mild apneic events (duration < 20 seconds), pretreatment with 100% oxygen effectively eliminated most of the increase in sympathetic nerve activity. In a similar study, Smith and colleagues<sup>31</sup> found that longer apneic events while breathing oxygen produced a modest increase in sympathetic nerve activity, the magnitude of which was greatly attenuated relative to apneic events while breathing room air. Together these studies show that hypoxemia plays the predominant role in mediating the sympathoexcitation, although other factors also contribute. Hypercapnia alone, when sufficiently severe, can increase sympathetic nerve activity, but it appears that the synergistic interaction between hypercapnia and hypoxia is the more important effect at the Pco<sub>2</sub> levels achieved during apnea.<sup>33,34</sup> Ventilation can impose an inhibitory effect on sympathetic nerve activity,<sup>35</sup> but this effect is removed during apneas. An apneic episode therefore causes disinhibition of respiratory modulation of sympathetic nerve activity, thereby allowing the chemoreceptor activation to predominate in mediating the sympathoexcitation.

### Cardiovascular Responses

The increase in sympathetic nerve activity is accompanied by several changes in the cardiovascular system.<sup>29,36,37</sup> An increase in activity at the end of each apneic event leads to vasoconstriction, in-

creasing peripheral vascular resistance in the systemic and oftentimes pulmonary vasculature, and resulting in a progressive rise in arterial pressure, as shown by the tracing in Figure 1. Other studies have shown that arousal from non-REM sleep elicits an increase in peripheral vascular resistance and arterial pressure.<sup>38,39</sup> In addition, patients with OSA have been found to have higher levels of sympathetic activity (nerve activity and catecholamine levels) while awake compared with nonapneic persons.<sup>21,31,32,40</sup> Effective treatment of OSA has been found to decrease daytime sympathetic nerve activity,<sup>32,41</sup> thus supporting the link between increased daytime sympathetic nerve activity and OSA.

This chronic increase in daytime sympathetic nerve activity has been implicated in the development of daytime hypertension and cardiac arrhythmias.<sup>5,21,29,36</sup> In addition, OSA has been shown to be associated with increased risk for stroke,<sup>42</sup> coronary artery disease,<sup>43</sup> and congestive heart failure.<sup>44</sup> Compared with the general US population, OSA patients are twice as likely to have hypertension and three times as likely to have ischemic heart disease, and have four times as much cerebrovascular disease.<sup>45</sup> Although there is a generalized increase in cardiovascular morbidity, in the following section we focus on two major cardiovascular disease processes associated with OSA, namely, hypertension and cardiac arrhythmias.

### *Hypertension*

For years researchers have investigated a causal relation between OSA and daytime hypertension. One primary impetus for these investigations could be the recognition that as much as 40% of patients with resistant essential hypertension have undiagnosed OSA.<sup>5,17-19</sup> Moreover, the relation between OSA and daytime hypertension seems to be strongest in those who are younger than 50 years.<sup>5,46-48</sup> Although some studies suggesting a link between OSA and hypertension have been criticized for not controlling for possible confounding variables (obesity, male sex, coexisting disease, preexisting drug therapy, and age), most of the literature strongly suggests that OSA can cause persistent hypertension.<sup>5</sup> Recent data from a study of 1,741 patients (741 men; 1,000 women) found OSA to be independently associated with hypertension in both men and women, while controlling for possible confounders (age, body mass index, sex, menopause

or hormone replacement therapy, alcohol use, smoking, and race).<sup>49</sup>

In dogs, occlusion of the upper airway (simulating OSA) has been shown to induce chronic hypertension.<sup>50</sup> In humans, several researchers have shown a significant association between OSA and hypertension after controlling for body mass index.<sup>25</sup> In addition, Young et al<sup>51</sup> found that the apnea-hypopnea index was predictive of both sleep and daytime blood pressure. These data suggest that as OSA worsens, there is a concomitant increase in both sleep and daytime blood pressure. Several other studies have also shown a similar dose-response relation between OSA and blood pressure.<sup>25,46,48,49</sup> Recent data from the Sleep Heart Health Study indicate an association between OSA and hypertension in 6,132 middle-aged to older men and women of different ethnic backgrounds.<sup>52</sup>

The cause of a dose-response relation between the severity of OSA and blood pressure is most likely multifaceted. As noted above, during OSA there are both acute and chronic increases in sympathetic nerve activity, which have been implicated in the increased sleep and daytime blood pressure. In addition, given that many OSA patients are obese, the association between obesity and hypertension must not be neglected. This multifaceted nature of OSA and hypertension is further supported by the variability in blood pressure response to treatment of OSA. In addition to improving the symptoms associated with OSA, several studies have shown that treatment with nasal continuous positive airway pressure (nCPAP) or tracheostomy might lower both daytime and nighttime blood pressure in OSA patients.<sup>35,53-56</sup> The magnitude of this response varies and might be related to nocturnal desaturation frequency.<sup>55</sup>

Dimsdale et al<sup>54</sup> recently reported the results of a double-blind placebo-control trial comparing treatment of OSA in patients using nCPAP and placebo on nocturnal and daytime blood pressure. The placebo in this study was nCPAP at 2-cm H<sub>2</sub>O compared with nCPAP at 10-cm H<sub>2</sub>O in the treatment group. Results from this study suggest that, compared with placebo, treatment with nCPAP is associated with a greater decrease in nocturnal mean arterial blood pressure. Furthermore, the effectiveness of nCPAP compared with placebo in decreasing daytime mean arterial blood pressure is unclear. Dimsdale et al<sup>54</sup> did show a decrease in



daytime mean arterial blood pressure with treatment using both nCPAP and placebo for 7 days. There was no significant difference between the nCPAP and placebo trials, however. Whether this finding is the result of a true placebo effect or the result of an underpowered study is unclear. In a similar study Faccenda et al<sup>55</sup> reported a difference between nCPAP and placebo on both nocturnal and daytime blood pressure in OSA patients. Unlike the Dimsdale et al study, Faccenda et al used an oral placebo instead of nCPAP at 2-c m H<sub>2</sub>O.<sup>54,55</sup>

Although further research is needed to define more clearly the effects of treatment of OSA on blood pressure, it appears that treatment with nCPAP results in a modest decrease in nocturnal and daytime blood pressure. In addition, it is unclear from the data whether the effect of treatment of OSA on blood pressure is different in hypertensive patients compared with OSA patients with high normal blood pressures.<sup>56</sup> Most of the studies to date have primarily studied patients with high normal blood pressure. Furthermore, when left untreated, OSA leads to greater changes in daytime blood pressure, and eventually structural changes can occur within the vasculature to the point that treatment for the OSA will not effectively lower blood pressure. Thus, a possible reason that treatment of OSA in some cases is ineffective in lowering blood pressure might be that the hypertension has become an organic disease.

#### *Cardiac Arrhythmias*

The relation between cardiac arrhythmias and sleep apnea was assessed by several authors. While some found an increase in both bradyarrhythmias and tachyarrhythmias, others found a low incidence in patients without serious cardiac or pulmonary disease. This discrepancy is confounded by the unknown incidence of sleep apnea in the healthy persons, and the high incidence of hypertension and cardiovascular disease in patients with sleep apnea. Nevertheless, most experts agree that cardiac arrhythmias occur more frequently in patients who have sleep apnea and that the incidence increases with the number of apneic episodes and the degree of arterial oxygen desaturation.

*Bradyarrhythmias.* Atrioventricular block and asystoles have been reported in up to 10% of patients with sleep apnea. In a series of 400 patients with sleep apnea syndrome, sinus arrest (>2.5 seconds), second-degree atrioventricular block, and

sinus bradycardia were found in 11%, 8%, and 7% of patients, respectively.<sup>57</sup> There were no important differences in age, body weight, apnea-hypopnea index, or minimum oxygen saturation between those with and without arrhythmias. These arrhythmias, however, were observed only when oxygen saturation was less than 72%. Several studies have suggested that sinus bradycardia (<30 bpm) and sinus arrest (>2.5 seconds) do not occur in healthy asymptomatic persons, although second-degree atrioventricular block, namely, Mobitz type I, have been reported in up to 7% of cases.<sup>57</sup> Koehler et al<sup>58</sup> looked at the factors involved in the pathogenesis of heart block in patients with sleep apnea and have concluded that almost 90% of these episodes occur during rapid eye movement sleep and during an oxygen desaturation of at least 4%. In contrast to the previous reports by Guilleminault et al,<sup>57</sup> no oxygen saturation threshold value was found.

Recent studies have evaluated the electrophysiologic characteristics of the sinus node and conduction system of patients with sleep apnea.<sup>59–62</sup> These studies found that sinus node and atrioventricular conduction were normal or only slightly abnormal in all patients while awake, suggesting that the changes in heart rhythm are not due to fixed or anatomic disease of the sinus node and atrioventricular conduction system, but rather are due to autonomic changes, namely, an increase in vagal tone. That intravenous atropine administration eliminates the marked sinus arrhythmia and bradyarrhythmias observed in patients with sleep apnea syndrome<sup>61</sup> supports this hypothesis. Hypoxemia and cessation of breathing are essential for the development of bradycardia in patients with apnea, and the degree of bradycardia seems to correlate with the severity of hypoxemia.<sup>62</sup> The bradycardic response to hypoxia is usually counteracted by the hyperventilation at the termination of each apneic episode. As such, marked bradycardia is apparent only with the cessation of breathing during each apneic event.

*Tachyarrhythmias and ventricular ectopy.* Ventricular ectopy has been reported in up to 66% of patients with sleep apnea syndrome.<sup>63</sup> This incidence is significantly higher than what is reported in asymptomatic healthy persons (0% – 12%).<sup>57</sup> Unlike patients who do not have sleep apnea, patients with this syndrome experience ectopy mostly during sleep, suggesting a direct relation between

arrhythmias and sleep apnea. Similarly, ventricular tachycardia, although less common, is also more common in patients with sleep apnea (0% – 15%) compared with the general population (0% – 4%). In most studies, the occurrence of ventricular tachycardia is almost exclusive to apneic events.<sup>58,64</sup> The mechanism by which sleep apnea causes ventricular arrhythmias is not known, but the decrease in arterial oxygen saturation among other factors has been shown to play an important role. Shepard et al<sup>65</sup> studied the relation between ventricular ectopy and oxyhemoglobin desaturation in patients with OSA and found an increase in premature ventricular contraction frequency with oxygen saturation decreasing below 60%. The authors concluded that patients with OSA whose arterial oxygen saturation is less than 60% are at increased risk and should be managed accordingly.

## Diagnosis


The approach to patients with suspected sleep-related disorders should start with a thorough clinical evaluation, including a detailed history and physical examination, then a sleep study to confirm the diagnosis. A major challenge to diagnosis is the distinction between benign snoring and snoring related to apnea. A thorough investigation into the various signs and symptoms through a detailed history and a simple questionnaire to assess daytime sleepiness (The Stanford Sleepiness Scale<sup>66</sup> or the Epworth Sleepiness Scale<sup>67</sup>) can help measure the severity of the condition. Such an evaluation is particularly important for the elderly patient, who might have other disorders, such as nocturnal myoclonus and possibly dementia, that could render history taking harder.

The most common symptoms include chronic loud snoring, excessive daytime sleepiness, personality changes, fatigue, depression, headache, and impairment of thinking.<sup>68</sup> The physical examination should focus on ruling out any discrete anatomic lesion, located anywhere from the nasal vestibule to the larynx, that could increase the likelihood of an obstructive event. Common physical findings include septal deviation, adenotonsillar hypertrophy, retrognathia, and crowding of the upper airway structure. Assessment of nasal obstruction and oropharyngeal or hypopharyngeal narrowing is made using fiberoptic endoscopy. Fiberoptic

pharyngoscopy with the Mueller maneuver (forced expiration against closed upper airway) can replicate the obstructive events that occur during sleep in patients with OSA.<sup>69,70</sup> Obesity, increased nuchal circumference, and a high body mass index are also common. Other signs to look for are cor pulmonale, hypertension, bradycardia or asystole during sleep, and pedal edema.<sup>68,71</sup>

Based on the history, sleepiness scale scores, and physical examination, if OSA is highly suspected, then overnight polysomnography is strongly indicated. It should be emphasized that particular attention must be paid to the manifestations of OSA in the elderly because of the associated increase in morbidity and mortality. Indeed, several investigators have found that sleep apnea can increase vascular morbidity and possibly mortality in untreated cases.<sup>72</sup> In one study, the respiratory disturbance index was found to be an independent predictor of cardiovascular mortality in patients with coronary artery disease. A careful sleep history and polysomnography are therefore essential and should be obtained often in the workup of an elderly patient with cardiac disease or hypertension who has a history of loud snoring. A suggested approach to patients with a history of loud snoring is provided in Figure 2.

Because the cost of overnight polysomnography is expensive (\$1,000 – \$1,400), several different portable devices have been developed to record nocturnal breathing and oxygenation at home for the diagnosis of OSA.<sup>73</sup> Although the cost of these home studies is much less (\$400 – \$500) than overnight polysomnography, the home studies have been found to have a lower efficacy for OSA diagnosis compared with overnight polysomnography.<sup>74</sup> Recently, Chervin et al<sup>74</sup> performed a cost-utility analysis comparing polysomnography, home testing, and no sleep testing for the diagnosis of OSA. Polysomnography resulted in the greatest gain in 5-year quality-adjusted life-years (QALYs) compared with home testing and no sleep testing. Furthermore, Chervin et al showed that the incremental charges for polysomnography, compared with home testing or no testing, were \$13,400 and \$9,200, respectively, per QALY gained.<sup>74</sup> Compared with other medical procedures (ie, renal dialysis costs \$47,200 in 1996 dollars and screening asymptomatic patients for carotid stenosis costs about \$120,000 in 1997 dollars), the benefits gained



**Figure 2. Suggested approach to patients with a history of loud snoring. Please note that although symptoms of obstructive sleep apnea (OSA) are sufficient to proceed with polysomnography, a sleepiness scale and a complete physical examination should always be obtained in patients suspected of having OSA.**

from using overnight polysomnography for the diagnosis of OSA seem justified.<sup>74</sup>

### Clinical Management

An effective therapeutic approach must be started as soon as the diagnosis of sleep apnea has been established so that the associated morbidity and mortality are limited. Proper patient counseling pertinent to each treatment modality must be discussed. The ultimate goals are to restore airway patency and sleep continuity and to improve daytime functioning and quality of life. The resolution of the clinical signs and symptoms of OSA are reflected by a decrease in the apnea-hypopnea index and an increase in the oxyhemoglobin saturation level.<sup>71</sup> The treatment of sleep apnea entails modification of behavioral factors, medical treatment, use of nCPAP, application of oral or dental devices, and surgical procedures. Relief of the syn-

drome usually results in improved clinical symptoms.

### Nonsurgical Treatment

#### *Behavior Change and Pharmacologic Treatment*

Behavioral changes, such as weight loss, avoidance of alcohol, sedatives, antihistamines, and smoking, and body position training, are key in the management of patients with OSA. This therapy requires active patient participation, however, and rarely achieves the desired outcome.<sup>71,75</sup> Similarly, pharmacologic treatment with progesterone, mazindol, and other drugs has been scarcely effective and disappointing.<sup>76</sup>

#### *Nasal Continuous Positive Airway Pressure and Intraoral Appliances*

Currently, nCPAP is the most common and most successful treatment for OSA. Nasal CPAP functions as a pneumatic stent to keep the upper airway

open during inspiration by preventing the pharyngeal collapse associated with the negative inspiratory pressure. In addition, genioglossus dysfunction observed in patients with OSA has been normalized after treatment with nCPAP.<sup>77</sup> Tousignant et al,<sup>78</sup> using the standard gamble method, showed an average gain of 5.4 QALYs in 19 patients whose OSA was treated with nCPAP. Furthermore, the cost-utility ratio in the Tousignant et al study was between Can\$3,397 and Can\$9,792 for each QALY.<sup>78</sup>

Compared with many other clinical interventions, nCPAP is clearly a cost-effective treatment choice for OSA. Moreover, nCPAP has consistently been shown to be effective in lowering the apnea-hypopnea index in OSA patients. For example, Clark et al<sup>79</sup> showed a 60% decrease in the apnea-hypopnea index in OSA patients managed with nCPAP. Tousignant et al,<sup>78</sup> using nCPAP, found improvement in 9 of 12 symptoms commonly associated with OSA. Furthermore, all patients in this study showed a decreased severity of polysomnographic indicators of OSA after treatment with nCPAP. Ferguson et al<sup>80</sup> also showed dramatic improvements in the apnea-hypopnea index with treatment. Before treatment, patients had an average apnea-hypopnea index of  $17.6 \pm 13.2$ ; after treatment with nCPAP, the average apnea-hypopnea index was  $3.6 \pm 1.7$ . Using the Medical Outcomes Study Short Form-36 questionnaire to assess quality of life in OSA patients, D'Ambrosio et al<sup>81</sup> found marked impairment of all aspects of quality of life (physical functioning 75%, vitality 41%, role functioning [physical 54%, emotional 61%, social 66%], general health 88%, and mental health 76%). After 8 weeks of treatment with nCPAP, the following improvements were seen: vitality 75%, social functioning 90%, and mental health 96%. Thus, nCPAP is consistently associated with a significant clinical outcome.

Although nCPAP has been shown to improve quality of life and survival,<sup>82</sup> its use is sometimes limited by poor long-term compliance.<sup>83</sup> Nasopharyngeal symptoms that are common in patients with OSA, such as dryness, sneezing, mucous in the throat, blocked nose, and rhinorrhea, tend to increase with use of nCPAP.<sup>84</sup> Intraoral appliances have been described as an alternative to nCPAP for the treatment of mild OSA. They modify the upper airway by either advancing the mandible or retain-


ing the tongue.<sup>85</sup> In one study, snoring improved in most patients, and OSA was diminished in approximately one half of patients.<sup>85</sup> Long-term compliance ranges from 50% to 100%, with excessive salivation and temporomandibular joint discomfort being the major complaints.<sup>85</sup>

Clark et al<sup>79</sup> compared the clinical efficacy of nCPAP and anterior mandibular positioning devices using a crossover clinical trial and found nCPAP to be clinically more effective than anterior mandibular positioning devices in treating OSA. The apnea-hypopnea index decreased on average 59.5% ( $33.86 \pm 14.30$  to  $11.15 \pm 3.93$ ) with nCPAP treatment compared with 38.9% ( $33.86 \pm 14.30$  to  $19.94 \pm 12.75$ ) using anterior mandibular positioning devices. Participants in the study did prefer the anterior mandibular positioning devices to the nCPAP, however. In a similar study, Ferguson et al<sup>80</sup> used a randomized crossover clinical trial to compare nCPAP with anterior mandibular positioning devices. The apnea-hypopnea index decreased from  $17.6 \pm 13.2$  to  $3.6 \pm 1.7$  using nCPAP compared with a decrease from  $19.7 \pm 13.8$  to  $9.7 \pm 7.3$  with anterior mandibular positioning devices. Similar to the Clark et al study findings, patients in the Ferguson et al study overwhelmingly preferred the anterior mandibular positioning devices to nCPAP. Treatment with anterior mandibular positioning devices appears, therefore, to be a realistic alternative to nCPAP in patients who are noncompliant with nCPAP.

### **Surgical Treatment**

Surgical treatments of OSA include invasive procedures that carry certain risks and might not be uniformly effective.<sup>71</sup> The goal of surgery is to augment the upper airway and relieve any obstruction. When nasal symptoms are the primary complaint, nasal surgery includes septoplasty, turbinectomy, or repair of alar collapse, when necessary. When the obstruction is at the velopharyngeal level, the surgery of choice is uvulopalatopharyngoplasty. This single-staged procedure involves removal of part of the soft palate, uvula, and tonsils, as well as part of the posterior pharyngeal wall. The success rate of this surgery is nearly 50% to 60% at 4 years.<sup>86</sup> This low figure has been attributed to poor patient selection. Potential complications include difficult intubation, hemorrhage, nasal regur-





**Figure 3. Suggested approach to management of patients with obstructive sleep apnea. A more aggressive approach might be justified for patients with serious coexisting cardiovascular conditions.**

gitation or stenosis, velopharyngeal insufficiency, and voice and resonance change.

Laser-assisted uvulopalatoplasty has been introduced as an office setting procedure to treat patients with loud snoring.<sup>87</sup> A carbon dioxide laser is used to create full-thickness vertical trenches on either side of the uvula, thereby shortening and thinning this structure. Nevertheless, despite a reduction in snoring frequency and loudness, there is little evidence to support its use in the treatment of OSA. Other surgical procedures, such as midline glossectomy to reduce the bulk of the tongue and maxillomandibular osteotomy and advancement to increase the retrolingual space, have also been used to treat persistent snoring and OSA.<sup>88,89</sup> The rationale is to augment the posterior airway space at the base of the tongue. In patients with severe OSA and morbid obesity, tracheotomy is still a highly effective alternative.<sup>71</sup> A suggested algorithm for the management of patients with OSA is provided in Figure 3.

#### ***Treatment of Cardiac Arrhythmias***

Patients with OSA have been shown to suffer from high morbidity and mortality. In a study conducted by Partinen et al,<sup>90</sup> the mortality rate in patients managed with weight loss only was 11 of 100 patients in 5 years, and almost one half was due to vascular events. He et al<sup>91</sup> calculated the cumulative survival in 385 OSA patients and found the probability of cumulative 8-year survival to be  $0.96 \pm 0.02$  (SE) in patients with an apnea index of less than 20, and  $0.63 \pm 0.17$  for an apnea index of more than 20. Despite a higher mortality rate, a cause-and-effect relation between cardiac arrhythmias and death in patients with sleep apnea has not been established. What has been shown is a decrease in the incidence of death after certain therapies in patients who have OSA. In his study of 385 men with OSA, He et al<sup>91</sup> found that none of the patients treated with tracheostomy or nCPAP died. Similarly, Partinen et al<sup>90</sup> found a 0% mortality

rate per 100 patients per 5 years in the surgically treated population.

### *Bradyarrhythmias*

Clinical decisions regarding the implantation of permanent pacemakers in patients with OSA-associated bradyarrhythmias can be difficult, largely because clear and accepted indications are lacking for pacemaker therapy. Published guidelines regarding pacemaker implantation are notably sparse regarding the specific scenario of bradyarrhythmias occurring during sleep apnea,<sup>92</sup> and extrapolation from the existing recommendations is limited: most class I and class IIA indications specifically require either symptoms or a threshold degree of bradycardia in the awake state; these circumstances are by definition hard to define in the OSA patient.

Certainly, therapy for OSA is mandatory, but the additional role of pacemaker therapy is less clear. Bradycardia and heart block occurring during apneic episodes can be eliminated by treatment with nCPAP or tracheostomy,<sup>82,91</sup> and no fixed or structural conduction system abnormalities are apparent in most of these patients when evaluated by electrophysiology studies.<sup>60</sup> Nevertheless, no prospective outcome studies or randomized trials comparing pacemaker implantation with OSA treatment alone exist to validate or refute this approach.

Stegman et al<sup>93</sup> described OSA as a suspected cause of asymptomatic bradyarrhythmias in 7 patients. Treatment with nCPAP or tracheostomy was effective without adverse outcome for a mean of 22 months follow-up. In a retrospective review, Koehler et al<sup>61</sup> investigated the outcome of patients with sleep apnea-related bradyarrhythmias. Seventy-one men with OSA-associated bradyarrhythmias were compared with a group of 61 age- and weight-matched patients with OSA but no bradyarrhythmias. No causal relation between OSA-related bradyarrhythmias and mortality could be established.

In view of these limited observations and the pathophysiologic findings of OSA-related bradycardia discussed previously, it appears reasonable to reserve pacemaker implantation for those patients in whom symptomatic bradyarrhythmias persist despite effective treatment of OSA<sup>94</sup> or in whom therapy for OSA is unsatisfactory.<sup>95</sup>

### *Tachyarrhythmias*

Similarly, no information is available regarding the specific role of implantable cardiac defibrillators

or antiarrhythmic drug therapy in the management of ventricular arrhythmias in the setting of OSA. The frequency of ventricular tachycardia in patients with OSA might not be notably higher than in patients without OSA, and all reports of ventricular tachycardia in this population are of nonsustained ventricular tachycardia. There does appear to be a relation with OSA specifically in that these patients will characteristically have ventricular tachycardia during sleep. Thus, it would appear reasonable to perform electrophysiologic studies for risk stratification only in those patients with indications for a study based on symptoms during wakefulness. In our laboratories, we include patients with unexplained syncope or near syncope and patients with nonsustained ventricular tachycardia, concomitant coronary artery disease, and depressed ejection fraction. If the existence of substrate for ventricular tachycardia has been determined, it is likely that OSA might exacerbate the severity of ventricular tachycardia. As such, with treatment of OSA it is likely this exacerbation of ventricular tachycardia will be eliminated. Even so, further evaluation and treatment of persistent ventricular tachycardia should not be precluded after treatment of OSA.

### **Conclusion**

Sleep apnea is a common but underdiagnosed disorder with a multitude of related systemic manifestations beyond the well-recognized obstructive phenomena. Pathophysiologic understanding of this disorder is best approached from the perspective of integrated structural, neural, and cardiopulmonary relations. Indeed, the obstruction to airflow during sleep can occur at multiple anatomic levels and is dynamically responsive to hypoxic and hypercapnic reflexes. It is these responses, particularly the cyclical alterations in sympathetic nerve activity in response to apnea and recovery and the parasympathetic responses related to hypoxemia, that likely contribute to associated cardiovascular disease, namely, hypertension. In addition, frequently observed bradyarrhythmias and tachyarrhythmias appear to be the result of these autonomic fluctuations.

The reasons for the increased mortality in patients with sleep apnea are not established, but it is clear that therapy directed at alleviating the obstruction to airflow does improve patient outcomes.

nCPAP is the mainstay of treatment and, in fact, improves arrhythmic and cardiovascular disturbances as well. In selected patients, surgical therapy is still warranted, with tracheostomy the most common approach. Finally, the approach to cardiac arrhythmias should be done with an understanding of the autonomic changes that accompany an apneic episode. Daytime high-degree atrioventricular block might not be occurring during waking hours and thus might not require pacemaker implantation. Similarly, the approach to tachyarrhythmias in the setting of OSA should be similar to our management of ventricular arrhythmias in the absence of this disorder, as no specific recommendations are available for this population.

## References

- Kramer NR, Cook TE, Carlisle CC, Corwin RW, Millman RP. The role of the primary care physician in recognizing obstructive sleep apnea. *Arch Intern Med* 1999;159:965–8.
- Guilleminault C, Hoed JVD, Milner M. Clinical overview of the sleep apnea syndrome. In Guilleminault C, Dement WC, editors. *Sleep apnea syndromes*. New York: John Wiley & Sons, 1988:1–11.
- Chervin RD, Guilleminault C. Obstructive sleep apnea and related disorders. *Neurol Clin* 1996;14:583–609.
- Redline S, Strohl KP. Recognition and consequences of obstructive sleep apnea hypopnea syndrome. *Clin Chest Med* 1998;19:1–19.
- Silverberg DS, Oksenberg A, Iaina A. Sleep related breathing disorders are common contributing factors to the production of essential hypertension but are neglected, underdiagnosed, and undertreated. *Am J Hypertens* 1997;10(12 Pt 1):1319–25.
- Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med* 1993; 328:1230–5.
- Olson LG, King MT, Hensley MJ, Saunders NA. A community study of snoring and sleep-disordered breathing: Prevalence. *Am J Respir Crit Care Med* 1995;152:711–6.
- Lavie P. Sleep apnea in industrial workers. In Guilleminault C, Lugaresi E, editors. *Sleep-wake disorders: natural history, epidemiology and long-term evolution*. Philadelphia: Lippincott Raven Press, 1983:127–35.
- Stradling JR, Crosby JH. Predictors and prevalence of obstructive sleep apnoea and snoring in 1001 middle aged men. *Thorax* 1991;46:85–90.
- Gislason T, Benediksdottir B, Bjornsson JK, Kjartansson G, Kjeld M, Kristbjarnarson H. Snoring, hypertension, and the sleep apnea syndrome: an epidemiologic survey of middle-aged women. *Chest* 1993;103:1147–51.
- Bixler EO, Kales A, Soldatos CR, Vela-Bueno A, Jacoby JA, Scarone S. Sleep apneic activity in a normal population. *Res Commun Chem Pathol Pharmacol* 1982;36:141–52.
- Catterall JR, Calverely PM, Shapiro CM, Flenley DC, Douglas NJ. Breathing and oxygenation during sleep are similar in normal men and women. *Am Rev Respir Dis* 1985;132:86–8.
- Ancoli-Israel S, Kripke DF, Mason W. Characteristics of obstructive and central sleep apnea in the elderly: an interim report. *Biol Psychiatry* 1987;22: 741–50.
- Ancoli-Israel S, Klauber MR, Stepnowsky C, Estline E, Chinn A, Fell R. Sleep-disordered breathing in African-American elderly. *Am J Respir Crit Care Med* 1995;152(6 Pt 1):1946–9.
- Ambrogetti A, Olson LG, Saunders NA. Differences in the symptoms of men and women with obstructive sleep apnoea. *Aust N Z J Med* 1991;21:863–6.
- Redline S, Kump K, Tishler PV, Browner I, Ferrette V. Gender differences in sleep-disordered breathing in a community-based sample. *Am J Respir Crit Care Med* 1994;149(3 Pt 1):722–6.
- Silverberg DS, Oksenberg A. Essential and secondary hypertension and sleep-disordered breathing: a unifying hypothesis. *J Hum Hypertens* 1996;10:353–63.
- Strohl KP, Redline S. Recognition of obstructive sleep apnea. *Am J Respir Crit Care Med* 1996;154(2 Pt 1):279–89.
- Silverberg DS, Oksenberg A. Are sleep-related breathing disorders important contributing factors to the production of essential hypertension? *Curr Hypertens Rep* 2001;3:209–15.
- Sullivan C, Grunstein R, Marrone O, Berthon-Jones M. Sleep apnea pathophysiology: upper airway and control of breathing. In Guilleminault C, Partinen M, editors. *Obstructive sleep apnea syndrome: clinical research & treatment*. Philadelphia: Lippincott-Williams & Wilkins, 1990.
- Hedner J, Ejnell H, Sellgren J, Hedner T, Wallin G. Is high and fluctuating muscle nerve sympathetic activity in the sleep apnoea syndrome of pathogenetic importance for the development of hypertension? *J Hypertension Suppl* 1988;6:S529–S31.
- Hwang JC, St John WM, Barlett D Jr. Afferent pathways for hypoglossal and phrenic responses to changes in upper airway pressure. *Respir Physiol* 1984;55:341–54.
- Paparella MM, Shumrick DA, Gluckman JL, Myerhoff WL. *Otolaryngology*. 3rd ed. Philadelphia: W B Saunders, 1991.
- Olsen KD, Kern EB, Westbrook PR. Sleep and breathing disturbance secondary to nasal obstruction. *Otolaryngol Head Neck Surg* 1981;89:804–10.
- Carlson JT, Hedner JA, Ejnell H, Peterson LE.

- High prevalence of hypertension in sleep apnea patients independent of obesity. *Am J Respir Crit Care Med* 1994;150:72–7.
26. Carter R, Watenpaugh DE, Muentner NK, Wasmund SL, Wasmund WL, Smith ML. Attenuation of apnea-induced sympathoexcitation during periodic breathing efforts in sleep apneic patients. *Physiologist* 1999;42:A-10.
  27. Guilleminault C, Motta J, Mihm F, Melvin K. Obstructive sleep apnea and cardiac index. *Chest* 1986; 89:331–4.
  28. Coy TV, Dimsdale JE, Ancoli-Israel S, Clausen J. Sleep apnoea and sympathetic nervous system activity. *J Sleep Res* 1996;5:42–50.
  29. Fletcher EC. Sympathetic activity and blood pressure in the sleep apnea syndrome. *Respiration* 1997; 64(Suppl1):22–8.
  30. Leuenberger U, Jacob E, Sweer L, Waravdekar N, Zwillich C, Sinoway L. Surges of muscle sympathetic activity during obstructive apnea are linked to hypoxemia. *J Appl Physiol* 1995;79:581–8.
  31. Smith ML, Neidermaier ON, Hardy SM, Decker MJ, Strohl KP. Role of hypoxemia in sleep apnea-induced sympathoexcitation. *J Auton Nerv Syst* 1996;56:184–90.
  32. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. *J Clin Invest* 1995;96:1897–904.
  33. Somers VK, Mark AL, Zavala DC, Abboud FM. Influence of ventilation and hypocapnia on sympathetic nerve responses to hypoxia in normal humans. *J Appl Physiol* 1989;67:2095–100.
  34. Smith ML, Hardy SM, Dibner-Dunlap ME. Interactive effects of hypoxia and hypercapnia on sympathetic nerve activity in humans. *FASEB J* 1996;3: A567.
  35. Engleman HM, Gough K, Martin SE, Kingshott RN, Padfield PL, Douglas NJ. Ambulatory blood pressure on and off continuous positive airway pressure therapy for sleep apnea-hypopnea syndrome: effects in “non-dippers”. *Sleep* 1996;19:378–81.
  36. Weiss JW, Remsburg S, Garpestad E, Ringler J, Sparrow D, Parker JA. Hemodynamic consequences of obstructive sleep apnea. *Sleep* 1996;19:388–97.
  37. Tilkian AG, Guilleminault C, Schroeder JS, Lehman KL, Simmons FB, Dement WC. Hemodynamics in sleep-induced apnea. Studies during wakefulness and sleep. *Ann Intern Med* 1976;85:714–9.
  38. Ringler J, Garpestad E, Basner R, Weiss JW. Systemic blood pressure elevation after airway occlusion during NREM sleep. *Am J Respir Crit Care Med* 1994;150:1062–6.
  39. Morgan BJ, Crabtree DC, Puleo DS, Badr MS, Toiber F, Skatrud JB. Neurocirculatory consequences of abrupt change in sleep state in humans. *J Appl Physiol* 1996;80:1627–36.
  40. Carlson JT, Hedner J, Elam M, Ejnell H, Sellgren J, Wallin BG. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. *Chest* 1993;103:1763–8.
  41. Waravdekar NV, Sinoway LI, Zwillich CW, Leuenberger UA. Influence of treatment on muscle sympathetic nerve activity in sleep apnea. *Am J Respir Crit Care Med* 1996;153(4 Pt 1):1333–8.
  42. Palomaki H. Snoring and the risk of ischemic brain infarction. *Stroke* 1991;22:1021–5.
  43. Partinen M, Guilleminault C. Daytime sleepiness and vascular morbidity at seven-year follow-up in obstructive sleep apnea patients. *Chest* 1990;97:27–32.
  44. Bradley TD. Right and left ventricular functional impairment and sleep apnea. *Clin Chest Med* 1992; 13:459–79.
  45. Guilleminault C. Clinical features and evaluation of obstructive sleep apnea. In Kryger MH, Roth T, Dement WC, editors. *Principles and practices of sleep medicine*. Philadelphia, W B Saunders Company, 1994.
  46. Millman RP, Redline S, Carlisle C, Assaf AR, Levinson PD. Daytime hypertension in obstructive sleep apnea. Prevalence and contributing risk factors. *Chest* 1991;99:861–6.
  47. Gislason T, Aberg H, Taube A. Snoring and systemic hypertension—an epidemiological study. *Acta Med Scand* 1987;222:415–21.
  48. Grunstein R, Wilcox I, Yang TS, Gould Y, Hedner J. Snoring and sleep apnoea in men: association with central obesity and hypertension. *Int J Obes Relat Metab Disord* 1993;17:533–40.
  49. Bixler EO, Vgontzas AN, Lin HM, et al. Association of hypertension and sleep-disordered breathing. *Arch Intern Med* 2000;160:2289–95.
  50. Brooks D, Horner RL, Kozar LF, Render-Teixeira CL, Phillipson EA. Obstructive sleep apnea as a cause of systemic hypertension. Evidence from a canine model. *J Clin Invest* 1997;99:106–9.
  51. Young T, Finn L, Hla KM, Morgan B, Palta M. Snoring as part of a dose-response relationship between sleep-disordered breathing and blood pressure. *Sleep* 1996;19(10 Suppl):S202–5.
  52. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. *Sleep Heart Health Study*. *JAMA* 2000;283:1829–36.
  53. Suzuki M, Otsuka K, Guilleminault C. Long term nasal continuous positive airway pressure administration can normalize hypertension in obstructive sleep apnea patients. *Sleep* 1993;16:545–9.
  54. Dimsdale JE, Loreda JS, Profant J. Effect of continuous positive airway pressure on blood pressure: a placebo trial. *Hypertension* 2000;35(1 Pt 1):144–7.
  55. Faccenda JF, Mackay TW, Boon NA, Douglas NJ. Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. *Am J Respir Crit Care Med* 2001;163:344–8.



56. Akashiba T, Minemura H, Yamamoto H, Kosaka N, Saito O, Horie T. Nasal continuous positive airway pressure changes blood pressure “non-dippers” to “dippers” in patients with obstructive sleep apnea. *Sleep* 1999;22:849–53.
57. Guilleminault C, Connolly SJ, Winkle RA. Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. *Am J Cardiol* 1983;52:490–4.
58. Koehler U, Fus E, Grimm W, et al. Heart block in patients with obstructive sleep apnoea: pathogenetic factors and effects of treatment. *Eur Respir J* 1998; 11:434–39.
59. Grimm W, Hoffmann J, Kohler U, et al. Invasive electrophysiological evaluation of patients with sleep apnoea-associated ventricular asystole—methods and preliminary results. *J Sleep Res* 1995;4(Suppl 1):160–5.
60. Grimm W, Hoffmann J, Menz V, et al. Electrophysiologic evaluation of sinus node function and atrioventricular conduction in patients with prolonged ventricular asystole during obstructive sleep apnea. *Am J Cardiol* 1996;77:1310–4.
61. Koehler U, Wetzig T, Peter JH, Ploch T, Schafer PH, Stellwaag M. Morbiditat und Letalitat bei Schlafapnoe und nachtlischen Bradyarrhythmien [Morbidity and mortality in sleep apnea and nocturnal bradyarrhythmia]. *Dtsch Med Wochenschr* 1994;119:1187–93.
62. Zwillich C, Devlin T, White D, Douglas N, Weil J, Martin R. Bradycardia during sleep apnea. Characteristics and mechanism. *J Clin Invest* 1982;69: 1286–92.
63. Flemons WW, Remmers JE, Gillis AM. Sleep apnea and cardiac arrhythmias. Is there a relationship? *Am Rev Respir Dis* 1993;148:618–21.
64. Downey R 3rd, Perkin RM, MacQuarrie J. Upper airway resistance syndrome: sick, symptomatic but underrecognized. *Sleep* 1993;16:620–3.
65. Shepard JW Jr, Garrison MW, Grither DA, Dolan GF. Relationship of ventricular ectopy to oxyhemoglobin desaturation in patients with obstructive sleep apnea. *Chest* 1985;88:335–440.
66. Hoddes E, Dement WC, Zarcone V. The development and use of the Stanford Sleepiness Scale (SSS). *Psychophysiology* 1972;9:150.
67. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. *Sleep* 1991;14:540–5.
68. Olsen KD, Suh KW, Staats BA. Surgically correctable causes of sleep apnea syndrome. *Otolaryngol Head Neck Surg* 1981;89:726–31.
69. Katsantonis GP, Maas CS, Walsh JK. The predictive efficacy of the Muller maneuver in uvulopalatopharyngoplasty. *Laryngoscope* 1989;99(7 Pt 1):67–80.
70. Sher AE, Thorpy MJ, Shprintzen RJ, Spielman AJ, Burack B, McGregor PA. Predictive value of Muller maneuver in selection of patients for uvulopalatopharyngoplasty. *Laryngoscope* 1985;95:1483–7.
71. Khawaja IT, Phillips BA. Obstructive sleep apnea: diagnosis and treatment. *Hosp Med* 1998;vol:33–40.
72. Redline S, Young T. Epidemiology and natural history of obstructive sleep apnea. *Ear Nose Throat J* 1993;729:20–1, 24–6.
73. Ferber R, Millman R, Coppola M, et al. Portable recording in the assessment of obstructive sleep apnea. ASDA standards of practice. *Sleep* 1994;17:378–92.
74. Chervin RD, Murman DL, Malow BA, Totten V. Cost-utility of three approaches to the diagnosis of sleep apnea: polysomnography, home testing, and empirical therapy. *Ann Intern Med* 1999;130:496–505.
75. Henderson JH 2nd, Strollo PJ Jr. Medical management of obstructive sleep apnea. *Prog Cardiovasc Disc* 1999;41:377–86.
76. Mosso A. Periodische Athmung und Luxus-Athmung. *Arch Anat Physiol* 1886:37.
77. Carrera M, Barbe F, Sauleda J, Thomas M, Gomez C, Agusti AG. Patients with obstructive sleep apnea exhibit genioglossus dysfunction that is normalized after treatment with continuous positive airway pressure. *Am J Respir Crit Care Med* 1999;159:1960–6.
78. Tousignant P, Cosio MG, Levy RD, Groome PA. Quality adjusted life years added by treatment of obstructive sleep apnea. *Sleep* 1994;17:52–60.
79. Clark GT, Blumenfeld I, Yoffe N, Peled F, Lavie P. A crossover study comparing the efficacy of continuous positive airway pressure with anterior mandibular positioning devices on patients with obstructive sleep apnea. *Chest* 1996;109:1478–83.
80. Ferguson KA, Ono T, Lowe AA, Keenan SP, Fleetham JA. A randomized crossover study of an oral appliance vs nasal-continuous positive airway pressure in the treatment of mild-moderate obstructive sleep apnea. *Chest* 1996;109:1269–75.
81. D’Ambrosio C, Bowman T, Mohsenin V. Quality of life in patients with sleep apnea: effects of nasal continuous positive airway pressure—a prospective study. *Chest* 1999;115:123–9.
82. Sullivan CE, Grunstein RR. Continuous positive airway pressure in sleep-disordered breathing. In Kryger MH, Roth T, Dement WC, editors. *Principles and practice of sleep medicine*. Philadelphia: W B Saunders, 1994:694–705.
83. Krieger J. Long-term compliance with nasal continuous positive airway pressure (CPAP) in obstructive sleep apnea patients and nonapneic snorers. *Sleep* 1992;15(6 Suppl):S42–6.
84. Brander PE, Soirinsuo M, Lohela P. Nasopharyngeal symptoms in patients with obstructive sleep apnea syndrome. Effect of nasal CPAP treatment. *Respiration* 1999;66:128–35.
85. Schimdt-Nowara W, Lowe A, Wiegand L, Cartwright R, Perez-Guerra F, Menn S. Oral appliances

- for the treatment of snoring and obstructive sleep apnea: a review. *Sleep* 1995;18:501–10.
86. Larsson LH, Carlsson-Nordlander B, Svanborg E. Four-year follow-up after uvulopalatopharyngoplasty in 50 unselected patients with obstructive sleep apnea syndrome. *Laryngoscope* 1994;104(1 Pt 1):1362–8.
  87. Krespi YP, Keidar A. Laser-assisted uvulopalatoplasty for the treatment of snoring. Operative techniques in otolaryngology. *Head Neck Surg* 1994;5.
  88. Woodson BT, Fujita S. Clinical experience of lingualplasty as part of the treatment of severe obstructive sleep apnea. *Otolaryngol Head Neck Surg* 1992;107:40–8.
  89. Sher AE. The role of maxillomandibular surgery for treating obstructive sleep apnea. *Sleep* 1996;19(9 Suppl):S88–9.
  90. Partinen M, Jamieson A, Guilleminault C. Long-term outcome for obstructive sleep apnea syndrome patients. Mortality. *Chest* 1988;94:1200–04.
  91. He J, Kryger MH, Zorick FJ, Conway W, Roth T. Mortality and apnea index in obstructive sleep apnea. Experience in 385 male patients. *Chest* 1988;94:9–14.
  92. Gregoratos G, Chaitlin MD, Conill A, et al. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). *J Am Coll Cardiol* 1998;31:1175–209.
  93. Stegman SS, Burroughs JM, Henthorn RW. Asymptomatic bradyarrhythmias as a marker for sleep apnea: appropriate recognition and treatment may reduce the need for pacemaker therapy. *Pacing Clin Electrophysiol* 1996;19:899–904.
  94. Becker HF, Koehler U, Stammnitz A, Peter JH. Heart block in patients with sleep apnoea. *Thorax* 1998;53(Suppl 3):S29–32.
  95. Ogata N, Takatori H, Kamijima J, Tatsumi K, Kuriyama T. [A case of Pickwickian syndrome treated by implantation of a cardiac permanent pacemaker]. *Kokyu To Junkan* 1989;37:791–5.